ReviewCancers2015
Optimizing Management of Patients with Adult T Cell Leukemia-Lymphoma.
Review in Cancers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis.Virology journal · 2023Pooled it
- Brazilian Protocol for Sexually Transmitted Infections 2020: human T-cell lymphotropic virus (HTLV) infection.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- Synthetic (Molecules (Basel, Switzerland) · 2020Article
- Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cellsIranian journal of basic medical sciences · 2020Article
- Appropriate radiation dose for symptomatic relief and local control in patients with adult T cell leukemia/lymphoma.Journal of radiation research · 2019Article
- A 17-Year-Old Boy With Right Face Palsy, Left Leg Weakness, and Lytic Skull-Bone Lesions.Journal of the Pediatric Infectious Diseases Society · 2018Article
- Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.Current hematologic malignancy reports · 2018Review
- Evaluation of the role ofBlood research · 2017Article
- Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.Clinical medicine insights. Blood disorders · 2017Article
- Radiation Response of Human Leukemia/Lymphoma Cells was Improved by 7-Geranyloxycoumarin.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult T cell leukemia-lymphoma is a rare disease with a high mortality rate, and is challenging for the clinician. Early allogeneic stem cell transplant can confer durable remission. As novel therapeutic agents become available to treat T cell malignancies, it is increasingly important that medical oncologists, hematologists, and hematopathologists recognize and accurately diagnose adult T cell leukemia-lymphoma. There is no uniform standard of treatment of adult T cell leukemia-lymphoma, and clinical trials remain critical to improving outcomes. Here we present one management approach based on the recent advances in treatment for adult T cell leukemia-lymphoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.